Skip to main content

Oyster Point Pharma, Inc. (OYST)

NASDAQ: OYST · IEX Real-Time Price · USD
9.98
-0.19 (-1.87%)
After-hours:Oct 25, 2021 7:43 PM EDT
10.17
-0.98 (-8.79%)
At close: Oct 25, 4:00 PM
Market Cap264.57M
Revenue (ttm)n/a
Net Income (ttm)-79.46M
Shares Out25.99M
EPS (ttm)-3.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume491,919
Open11.22
Previous Close11.15
Day's Range10.00 - 11.36
52-Week Range10.00 - 25.89
Betan/a
AnalystsBuy
Price Target52.50 (+416.2%)
Est. Earnings DateNov 4, 2021

About OYST

Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratopathy. Oyster Point Pharma, Inc. was incorporated in 2015 and is headquartered in Princeto...

IndustryBiotechnology
IPO DateOct 31, 2019
Employees62
Stock ExchangeNASDAQ
Ticker SymbolOYST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OYST stock is "Buy." The 12-month stock price forecast is 52.50, which is an increase of 416.22% from the latest price.

Price Target
$52.50
(416.22% upside)
Analyst Consensus: Buy

News

Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.

6 days ago - Zacks Investment Research

Why Oyster Point Pharma Stock Is Sinking Today

The FDA approval of nasal spray Tirvaya didn't include data needed for the company to receive the second tranche in its credit facility.

6 days ago - The Motley Fool

FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma

The FDA has approved Oyster Point Pharma Inc (NASDAQ: OYST) Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of dry eye disease.  Tyrvaya Nasal Spray is the first and only nasal...

1 week ago - Benzinga

Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Si...

PRINCETON, N.J., Oct. 18, 2021 /PRNewswire/ -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that the U.S. Food and Drug Administration (FDA) has approved TYRVAYA™ (varenicline solution) Nas...

1 week ago - PRNewsWire

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f...

1 month ago - GlobeNewsWire

Oyster Point Inks License Pact With Ji Xing Pharma For Dry Eye Disease Candidates In Greater China

Oyster Point Pharma Inc (NASDAQ: OYST) has announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpiniclin...

2 months ago - Benzinga

Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights

PRINCETON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma” or “the Company”) a clinical-stage biopharmaceutical company focused on the discovery,...

2 months ago - GlobeNewsWire

Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize O...

PRINCETON, N.J., and SHANGHAI, China, Aug. 05, 2021 (GLOBE NEWSWIRE) --  Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and co...

2 months ago - GlobeNewsWire

Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021

Conference Call and Webcast Scheduled for August 5, 2021, 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for August 5, 2021, 4:30 p.m. Eastern Time

2 months ago - GlobeNewsWire

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fi...

2 months ago - GlobeNewsWire

Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors

Donald Santel joins as Chairman of the Board of Directors Donald Santel joins as Chairman of the Board of Directors

2 months ago - GlobeNewsWire

Oyster Point Pharma Announces Preclinical Data Highlighting Potent Activity of OC-01 (varenicline) and OC-02 (simpini...

PRINCETON, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced preclinical data in non-human primates and in vitro models evaluating OC-01 (varenicline) nas...

3 months ago - GlobeNewsWire

Oyster Point Pharma Provides Key Supply Chain Insight For OC-01 (varenicline) Nasal Spray

PRINCETON, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced information regarding a key supply chain insight for OC-01 (varenicline) nasal spray followin...

3 months ago - GlobeNewsWire

Oyster Point Pharma to Participate in the LifeSci Partners Genetic Medicines Summit

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

4 months ago - GlobeNewsWire

Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline...

PRINCETON, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

4 months ago - GlobeNewsWire

Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics (APT) to Target Ophthalmic Diseases

PRINCETON, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

4 months ago - GlobeNewsWire

Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic Keratopathy

Oyster Point Pharma Inc (NASDAQ: OYST) has announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene Therapy and proof-of-concept in vivo study results from its firs...

4 months ago - Benzinga

Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Th...

PRINCETON, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

4 months ago - GlobeNewsWire

Oyster Point Pharma Reports First Quarter 2021 Financial Results and Recent Business Highlights

PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on the discovery...

5 months ago - GlobeNewsWire

New Strong Sell Stocks for May 6th

OYST, CDAY, GWPH, HRTG, and NATI have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2021

Other symbols:CDAYHRTGNATI
5 months ago - Zacks Investment Research

Oyster Point Pharma Announces Clinical Data Presentation of OC-01 (varenicline) Nasal Spray for Dry Eye Disease at th...

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of firs...

5 months ago - GlobeNewsWire

Oyster Point Pharma Announces New Appointment to Board of Directors

George Eliades joins the Board of Directors George Eliades joins the Board of Directors

6 months ago - GlobeNewsWire

Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for ...

PRINCETON, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fi...

7 months ago - GlobeNewsWire

Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of fir...

8 months ago - GlobeNewsWire

Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), a clinical-stage biopharmaceutical company focused on the discover...

8 months ago - GlobeNewsWire